Oral small molecule GLP-1 receptor agonist
HRS-7535 30 mg tablet once daily
HRS7535_PO_30MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.58 (0.01 to 45.14) | 0.45 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.19 (0.87 to 5.82) | 0.50 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.77 (0.85 to 20.93) | 0.21 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.27 (0.52 to 11.77) | 0.23 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 6.47 (0.66 to 96.23) | 0.20 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.52 (1.80 to 19.83) | 0.24 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.38 (0.68 to 9.41) | 0.52 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.84 (0.85 to 10.90) | 0.28 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.79 (0.05 to 13.22) | 0.49 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 1.13 (0.07 to 16.41) | 0.42 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -0.83 (-11.97 to 9.94) | 0.29 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -0.32 (-6.68 to 6.36) | 0.11 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -0.66 (-7.10 to 6.96) | 0.10 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.84 (0.05 to 8.30) | 0.57 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.82 (0.10 to 24.68) | 0.50 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.53 (0.78 to 9.80) | 0.63 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.01 (1.15 to 17.98) | 0.51 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.00 (0.64 to 6.67) | 0.48 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.24 (0.00 to 6.18) | 0.84 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.39 (0.00 to 15.93) | 0.73 |
| Chronic kidney disease with diabetes | Serious adverse events | longest follow-up | Placebo | HR 2.21 (0.43 to 14.18) | 0.28 |
| Chronic kidney disease with diabetes | Discontinuation due to adverse events | longest follow-up | Placebo | HR 6.29 (0.58 to 94.77) | 0.20 |
| Chronic kidney disease with diabetes | Nausea | longest follow-up | Placebo | HR 5.27 (1.17 to 23.35) | 0.29 |
| Chronic kidney disease with diabetes | Vomiting | longest follow-up | Placebo | HR 2.30 (0.50 to 10.75) | 0.64 |
| Chronic kidney disease with diabetes | Diarrhea | longest follow-up | Placebo | HR 2.67 (0.54 to 13.12) | 0.47 |
Trials
- SOLID-DKDA Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Diabetic Kidney Disease in Type 2 Diabetes2024 · 281 randomized · 16 weeks
- NCT06250946A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in Obese Subjects2024 · 235 randomized · 36 weeks